Rachel Zatkin Kizuka, NP
Nurse Practitioner · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Rachel Zatkin Kizuka’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$17,225
Medicare paid this office $17,225 for 96 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 52 | $10,012 | $141 |
| Return visit (30+ min) | 17 | $2,004 | $100 |
| New patient visit (45+ min) | 11 | $1,492 | $136 |
| Short return visit (20+ min) | 12 | $1,281 | $75 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $306 | $13 |
Who their Medicare patients are
96 Original Medicare patients in 2024. Average age 76 · Women 58% · Health risk score 0.98. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 50% · Coronary heart disease 20% · Cancer 16% · Diabetes 14% · Atrial fibrillation 14% · Depression 11%.
The office billed $65,507, Medicare allowed $22,501 and paid $17,225; for 165 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 96 | 165 | 76 | 0.98 | $65,507 | $17,225 |
| 2023 | 51 | 71 | 75 | 0.88 | $30,009 | $8,073 |
| 2022 | 120 | 163 | 77 | 0.95 | $70,764 | $19,778 |
| 2021 | 120 | 171 | 77 | 0.91 | $65,184 | $18,922 |
| 2020 | 13 | 14 | 78 | 1.08 | $4,500 | $1,337 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 31 | $4,588 | $135 |
| Return visit (30+ min) | 14 | $1,490 | $99 |
2022: 4 services
| Long return visit (40+ min) | 66 | $10,390 | $139 |
| New patient visit (60+ min) | 17 | $2,877 | $169 |
| New patient visit (45+ min) | 23 | $2,788 | $121 |
| Return visit (30+ min) | 16 | $1,704 | $107 |
2021: 5 services
| Long return visit (40+ min) | 65 | $10,132 | $141 |
| New patient visit (60+ min) | 14 | $2,521 | $180 |
| New patient visit (45+ min) | 19 | $2,371 | $125 |
| Return visit (30+ min) | 17 | $1,891 | $100 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $731 | $25 |
Drugs they prescribed that Part D paid
$73,334
Pharmacies billed $73,334 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 146) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
115 generic and fewer than 11 brand-name prescriptions · $73,334 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mesalamine | 13 | $3,563 | $274 |
| Sod Sulf-Potass Sulf-Mag Sulf | 21 | $1,441 | $69 |
| Cholestyramine | 11 | $1,188 | $108 |
| Omeprazole | 18 | $549 | $31 |
| Pantoprazole | 11 | $205 | $19 |
See all 6 drugs
| Mesalamine | 13 | $3,563 | $274 |
| Sod Sulf-Potass Sulf-Mag Sulf | 21 | $1,441 | $69 |
| Cholestyramine | 11 | $1,188 | $108 |
| Omeprazole | 18 | $549 | $31 |
| Pantoprazole | 11 | $205 | $19 |
| Nortriptyline | 11 | $117 | $11 |
Year by year
| 2024 | 146 | 60 | 0% (0) | None | $73,334 |
| 2023 | 118 | 49 | 0% (0) | 32% | $277,377 |
| 2022 | 397 | 285 | 0% (0) | 56% | $280,555 |
| 2021 | 72 | 47 | 0% (0) | 39% | $32,883 |
| 2020 | 13 | None | 0% (0) | None | $1,942 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Mesalamine | 15 | $4,383 | $292 |
| Sod Sulf-Potass Sulf-Mag Sulf | 12 | $856 | $71 |
| Omeprazole | 11 | $264 | $24 |
2022: 7 drugs
| Suprep | 84 | $9,666 | $115 |
| Sod Sulf-Potass Sulf-Mag Sulf | 107 | $8,401 | $79 |
| Mesalamine | 17 | $6,200 | $365 |
| Cholestyramine | 17 | $1,897 | $112 |
| Peg 3350-Electrolyte | 48 | $939 | $20 |
| Omeprazole | 17 | $299 | $18 |
| Famotidine | 13 | $156 | $12 |
Money from drug and device companies
$921 in 2025
| 2025 | 6 | 33 | None | $921 |
| 2024 | 2 | 3 | None | $246 |
| 2023 | 2 | 4 | None | $164 |
| 2022 | 2 | 4 | None | $72 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $450 | 17 payments
|
| Abbvie | Rinvoq | $210 | 10 payments
|
| Genzyme | Dupixent | $123 | 1 payment
|
| Lilly USA | Omvoh | $95 | 3 payments
|
| Pfizer | Velsipity | $24 | 1 payment
|
| Braintree Laboratories | Suflave | $19 | 1 payment
|
See all 33 published payments
| Janssen Biotech | Meals · 2025-10-20 | Tremfya | $16 |
| Abbvie | Meals · 2025-10-18 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $19 |
| Abbvie | Meals · 2025-09-29 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-09-23 | Tremfya | $37 |
| Abbvie | Meals · 2025-09-19 | None | $27 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $32 |
| Janssen Biotech | Meals · 2025-09-05 | Tremfya | $5 |
| Janssen Biotech | Meals · 2025-09-05 | Tremfya | $13 |
| Janssen Biotech | Meals · 2025-09-05 | Tremfya | $8 |
| Abbvie | Meals · 2025-09-05 | Linzess | $31 |
| Janssen Biotech | Meals · 2025-08-27 | Tremfya | $30 |
| Janssen Biotech | Meals · 2025-08-21 | Tremfya | $8 |
| Genzyme | Meals · 2025-08-20 | Dupixent | $123 |
| Lilly USA | Meals · 2025-08-05 | Omvoh | $29 |
| Abbvie | Meals · 2025-07-31 | Skyrizi | $8 |
| Janssen Biotech | Meals · 2025-07-29 | Tremfya | $22 |
| Janssen Biotech | Meals · 2025-07-18 | Tremfya | $24 |
| Lilly USA | Meals · 2025-07-14 | Omvoh | $35 |
| Janssen Biotech | Meals · 2025-07-11 | Tremfya | $5 |
| Janssen Biotech | Meals · 2025-07-11 | Tremfya | $18 |
| Abbvie | Meals · 2025-07-08 | Rinvoq | $16 |
| Janssen Biotech | Meals · 2025-06-17 | Tremfya | $41 |
| Lilly USA | Meals · 2025-05-28 | Omvoh | $32 |
| Janssen Biotech | Meals · 2025-05-15 | Tremfya | $130 |
| Abbvie | Meals · 2025-05-09 | Rinvoq | $28 |
| Janssen Biotech | Meals · 2025-04-29 | Tremfya | $19 |
| Abbvie | Meals · 2025-04-24 | Creon | $19 |
| Braintree Laboratories | Meals · 2025-04-10 | Suflave | $19 |
| Abbvie | Meals · 2025-04-10 | Rinvoq | $16 |
| Janssen Biotech | Meals · 2025-04-08 | Tremfya | $23 |
| Abbvie | Meals · 2025-03-31 | Creon | $12 |
| Pfizer | Meals · 2025-02-06 | Velsipity | $24 |
See earlier years (2024, 2023, 2022)
2024: $246
| Lilly USA | Omvoh | $202 | 2 payments
|
| Abbvie | Rinvoq | $44 | 1 payment
|
2023: $164
| Abbvie | Rinvoq | $139 | 3 payments
|
| Lilly USA | None | $25 | 1 payment
|
2022: $72
| Celgene | Zeposia | $45 | 3 payments
|
| Janssen Biotech | Stelara | $28 | 1 payment
|
Professional record
- NPI
- 1841847167
- Licence
- CA 95012660, CA 95137059
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2019-08-21
- NPI last updated
- 2020-06-03
- NPI record certified
- 2020-06-03
This is when the NPI record was last certified, not a medical board exam.